Synexa is a specialized biomarker services provider, focused on the identification, development, analysis, and interpretation of biomarkers in clinical development programs. The company serves global biopharma clients, operating from a custom-designed central lab in Cape Town and a flow cytometry and biomarker lab in London. Synexa employs over 40 professional research scientists and operates a wide variety of latest-technology analytical platforms (including MSD, ELISA, Flow Cytometry, CBA, cell culture, micro-array, sequencing, PCR, mass spectrometry, and bioinformatics). Synexa works in collaborative partnership with clients, aiming to deliver insights that significantly improve the quality of early decision-making about drugs in the development pipeline.